Co-Diagnostics (CODX) Shares Rise as Ebola PCR Test and Point-of-Care Platform Development Advances

Co-Diagnostics Inc. (CODX) shares gained on June 2, 2026, after the molecular diagnostics company and its Indian joint venture CoSara Diagnostics announced they are accelerating development of an Ebola virus PCR test and a portable point-of-care platform. The initiative targets rapid detection in resource-limited settings. The test utilizes the company's CoPrimer technology to reduce false positives, while the platform aims to deliver results outside centralized labs. No financial terms or regulatory timeline were disclosed. Co-Diagnostics, based in Salt Lake City, holds a significant stake in CoSara, which manufactures diagnostics for the Indian market and other regions. Investors reacted positively to the update, though the companies did not specify when the Ebola test might seek emergency use authorization or reach commercialization. The move expands Co-Diagnostics' infectious disease portfolio, which previously focused on COVID-19 and tuberculosis assays.